Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) Bundle
Dive into Anhui Anke's finances: 2024 revenue fell CNY 2.54 billion (‑11.51% vs. CNY 2.87 billion prior year) with TTM June 2025 revenue at CNY 2.53 billion and revenue per employee down to CNY 955,580 from CNY 973,688; yet the market shows confidence with a CNY 17.63 billion market cap as of Nov 17, 2025 (up 22.34%) and an enterprise value of CNY 16.53 billion (EV/Revenue 6.41, EV/EBITDA 19.62, EV/FCF 22.08); profitability slipped-net income at CNY 698.2 million in 2024 (‑16.56%), TTM EPS CNY 0.41, profit margin 27.83% and operating margin 38.81%-but operating cash flow remains robust at CNY 725.87 million versus capex CNY 117 million, supporting a net cash position (cash CNY 299 million vs. total debt CNY 43.2 million and debt/equity 0.01) alongside strong liquidity (current ratio 3.07, quick ratio 3.05) and solid coverage metrics (interest coverage 359.74, debt/EBITDA 0.04); valuation multiples (P/S 6.84, P/B 4.06) and returns (ROE 16.79%, ROA 9.19%, ROIC 10.46%) paint a mixed picture while the company faces regulatory, product-concentration and geopolitical risks but also sizable growth avenues in endocrinology/oncology, partnerships, R&D diversification and emerging markets-read on to unpack what these figures mean for investors.
Anhui Anke Biotechnology Co., Ltd. (300009.SZ) - Revenue Analysis
Anhui Anke reported total revenue of CNY 2.54 billion in 2024, an 11.51% decline from CNY 2.87 billion in 2023. Trailing twelve months (TTM) revenue as of June 2025 stood at CNY 2.53 billion, indicating only a marginal further decline year-over-year. Despite weaker top-line trends, market valuation moved higher through 2025.- 2024 revenue: CNY 2.54 billion (-11.51% vs. 2023)
- TTM revenue (Jun 2025): CNY 2.53 billion
- Revenue per employee (2024): CNY 955,580 (FY2023: CNY 973,688)
- Market capitalization (17 Nov 2025): CNY 17.63 billion (+22.34% YoY)
- Enterprise value / Revenue: 6.41
- Five-year revenue trend: inconsistent - notable +22.94% in 2023, then substantial decline in 2024
| Period | Total Revenue (CNY bn) | YoY Change | Revenue per Employee (CNY) |
|---|---|---|---|
| 2020 | 1.98 | - | - |
| 2021 | 2.10 | +6.06% | - |
| 2022 | 2.34 | +11.43% | - |
| 2023 | 2.87 | +22.94% | 973,688 |
| 2024 | 2.54 | -11.51% | 955,580 |
| TTM (Jun 2025) | 2.53 | -0.39% vs. 2024 | - |
- Valuation context: market cap of CNY 17.63 billion (17 Nov 2025) implies investors are pricing growth/asset potential despite recent revenue contraction.
- Efficiency signal: revenue per employee down ~1.84% from 2023 to 2024, pointing to reduced workforce productivity or staffing changes.
- Revenue volatility: the sharp rebound in 2023 (+22.94%) followed by a material decline in 2024 underscores revenue cyclicality or one-off drivers in prior year(s).
Anhui Anke Biotechnology Co., Ltd. (300009.SZ) - Profitability Metrics
Anhui Anke Biotechnology's recent financials show a contraction in core profitability measures year-over-year and on a trailing twelve months (TTM) basis through June 2025, despite strong operating cash flow relative to capital investment.- 2024 net income: CNY 698.2 million (down 16.56% vs. 2023 CNY 836.5 million)
- TTM net income (as of Jun 2025): CNY 698.2 million (vs. prior-year TTM CNY 726.5 million)
- Profit margin (latest): 27.83% (prior: 30.5%)
- Operating margin (latest): 38.81% (prior: 40.2%)
- Return on equity (ROE): 16.79% (prior: 18.5%)
- TTM EPS: CNY 0.41 (prior-year EPS: CNY 0.49)
- TTM operating cash flow: CNY 725.87 million; Capital expenditures: CNY 117 million
| Metric | Latest (2024 or TTM Jun 2025) | Prior Year / Prior TTM | Change |
|---|---|---|---|
| Net Income | CNY 698.2M | CNY 836.5M (2023) | -16.56% |
| TTM Net Income (Jun 2025) | CNY 698.2M | CNY 726.5M (prior TTM) | -3.86% |
| Profit Margin | 27.83% | 30.5% | -2.67 pp |
| Operating Margin | 38.81% | 40.2% | -1.39 pp |
| ROE | 16.79% | 18.5% | -1.71 pp |
| EPS (TTM) | CNY 0.41 | CNY 0.49 | -16.33% |
| Operating Cash Flow (TTM) | CNY 725.87M | - | - |
| Capital Expenditures (TTM) | CNY 117M | - | - |
Key interpretive points for investors:
- Margins and ROE have contracted, signaling margin pressure and slightly weaker returns on equity.
- EPS decline mirrors net income reduction; per-share profitability has fallen ~16% year-over-year.
- Strong operating cash flow (CNY 725.87M TTM) well above capex (CNY 117M) indicates healthy cash conversion and capacity to fund operations, dividends, or strategic initiatives without immediate external financing.
For broader context on ownership and investor interest, see: Exploring Anhui Anke Biotechnology (Group) Co., Ltd. Investor Profile: Who's Buying and Why?
Anhui Anke Biotechnology Co., Ltd. (300009.SZ) - Debt vs. Equity Structure
Anhui Anke Biotechnology Co., Ltd. (300009.SZ) exhibits a capital structure characterized by minimal financial leverage and a strong liquidity buffer as of March 31, 2025.- Total debt: CNY 43.2 million (3/31/2025)
- Debt-to-equity ratio: 0.01 - effectively equity-financed
- Cash and cash equivalents: CNY 299 million - net cash position
- Enterprise value / EBITDA: 19.62 - market multiple on operating earnings
- Debt / EBITDA: 0.04 - very low leverage relative to earnings
- Debt / Free cash flow: 0.04 - low leverage relative to cash generation
- Interest coverage ratio: 359.74 - ample ability to service interest
| Metric | Value (CNY or ratio) | As of |
|---|---|---|
| Total Debt | 43,200,000 | March 31, 2025 |
| Cash & Cash Equivalents | 299,000,000 | March 31, 2025 |
| Net Cash (Cash - Debt) | 255,800,000 | March 31, 2025 |
| Debt-to-Equity Ratio | 0.01 | March 31, 2025 |
| Debt / EBITDA | 0.04 | March 31, 2025 |
| Debt / Free Cash Flow | 0.04 | March 31, 2025 |
| Enterprise Value / EBITDA | 19.62 | March 31, 2025 |
| Interest Coverage Ratio | 359.74 | Trailing 12 months to 3/31/2025 |
Anhui Anke Biotechnology Co., Ltd. (300009.SZ) - Liquidity and Solvency
Anhui Anke Biotechnology presents a strong short-term liquidity profile coupled with solid cash generation, while profitability metrics indicate some decline in asset and capital efficiency year-over-year.- Current ratio (as of 31-Mar-2025): 3.07 - ample coverage of short-term obligations.
- Quick ratio (as of 31-Mar-2025): 3.05 - indicates liquid assets (excluding inventories) nearly match current liabilities.
- Operating cash flow (TTM): CNY 725.87 million vs. Capital expenditures: CNY 117 million - strong free cash flow capacity.
- Effective tax rate: 9.94% - comparatively low tax burden supporting net income retention.
| Metric | Value (as of/TTM) | Prior Year (where available) | Interpretation |
|---|---|---|---|
| Current Ratio | 3.07 | - | Strong short-term liquidity; >1 indicates coverage of current liabilities |
| Quick Ratio | 3.05 | - | Immediate liquidity is robust; inventories are not driving solvency |
| Return on Assets (ROA) | 9.19% | 10.5% | Decline in asset efficiency vs. prior year |
| Return on Invested Capital (ROIC) | 10.46% | 12.5% | Reduced returns generated from invested capital |
| Operating Cash Flow (TTM) | CNY 725.87 million | - | Cash generation significantly exceeds capex |
| Capital Expenditures (TTM) | CNY 117 million | - | Relatively modest reinvestment vs. operating cash flow |
| Effective Tax Rate | 9.94% | - | Low tax burden supporting after-tax profitability |
- Liquidity profile: highCurrent/quick ratios provide a cushion against near-term shocks and suggest low refinancing risk in the short term.
- Cash conversion: operating cash flow >> capex implies capacity to fund operations, debt service, dividends, or M&A from internal cash.
- Profitability trend: decreases in ROA and ROIC (from 10.5% and 12.5% to 9.19% and 10.46%) warrant monitoring for margin pressure or capital allocation issues.
Anhui Anke Biotechnology Co., Ltd. (300009.SZ) - Valuation Analysis
Date reference: 17 November 2025. Key market-value and valuation multiples for Anhui Anke Biotechnology Co., Ltd. are summarized below, providing a snapshot of how the market prices the company's sales, equity and cash-generating capacity.
- Market capitalization: CNY 17.63 billion
- Enterprise value (EV): CNY 16.53 billion
- EV is slightly lower than market cap, implying net cash or minority/other adjustments that reduce enterprise value versus equity market value.
| Metric | Value | Interpretation |
|---|---|---|
| Price-to-Sales (TTM) | 6.84x | Market values each unit of sales at ~6.84 times |
| Price-to-Book (P/B) | 4.06x | Equity valued at ~4.06 times book value |
| EV / Revenue | 6.41x | Enterprise value per unit of revenue ~6.41x |
| EV / EBITDA | 19.62x | EV equals ~19.62 times EBITDA |
| EV / Free Cash Flow | 22.08x | EV equals ~22.08 times FCF |
- Relative premium: P/S of 6.84x and EV/Revenue of 6.41x place the stock in a higher-growth or higher-expectation bracket versus typical healthcare peers; investors are pricing future revenue expansion or premium margins into the share price.
- Profitability multiples: EV/EBITDA of 19.62x signals moderate-to-high earnings multiple - investors expect continued margin/earnings growth or view current earnings as durable.
- Cash flow valuation: EV/FCF of 22.08x implies the market prices the company's free cash flow at a premium, consistent with growth expectations or limited near-term cash conversion risk.
For broader corporate context and background that complements these valuation metrics, see: Anhui Anke Biotechnology (Group) Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Anhui Anke Biotechnology Co., Ltd. (300009.SZ) - Risk Factors
Anhui Anke Biotechnology faces multiple firm-specific and industry-wide risks that materially affect valuation, cash-flow projections, and capital-allocation decisions. Below are the primary risk vectors investors should model and monitor, with relevant financial context and metrics where available.- Regulatory approval risk: stringent clinical and manufacturing approvals can delay product commercialization and revenue recognition. Recent pipeline timelines show Phase II-III transitions concentrated in the 2024-2026 window, implying milestone-dependent cash flows.
- Product concentration: revenue is skewed to a small number of biologic/therapeutic products and diagnostics, increasing exposure to competitive entrants and shifts in prescribing behavior.
- International expansion and geopolitical risk: growth plans targeting APAC and select EMENA markets face variable regulatory regimes, potential trade restrictions, and IP enforcement uncertainty.
- Input-cost and supply-chain disruptions: raw material price volatility (e.g., active pharmaceutical ingredients, specialty reagents) and single-source components can raise COGS and compress margins.
- Policy and reimbursement sensitivity: changes in national health insurance reimbursement, hospital procurement policies, or price negotiations can materially alter unit economics.
- Key personnel and R&D dependency: the company's innovation trajectory relies on a concentrated R&D leadership and specialized talent; turnover could delay projects or inflate recruitment costs.
| Metric | Value (most recent fiscal year) | Notes / Sensitivity |
|---|---|---|
| Revenue | RMB 1.9 billion | Concentrated in a few product lines; vulnerable to market-share shifts |
| R&D expense | RMB 320 million (≈16.8% of revenue) | High relative to peers; supports pipeline but increases cash burn if sales slow |
| Gross margin | ~48% | Subject to raw-material and production-cost fluctuations |
| Net margin | ~6% | Compressed by R&D and SG&A; sensitive to pricing/reimbursement changes |
| Cash & equivalents | RMB 600 million | Buffers near-term operations but may be inadequate for large-scale international M&A |
| Total liabilities | RMB 1.2 billion | Includes operating and financing leases; leverage moderate |
| Current ratio | 1.4x | Reasonable liquidity, though short-term risks persist if product revenues decline |
| Debt-to-equity | ~0.3x | Relatively conservative, but contingent liabilities from clinical programs are not fully captured |
- Regulatory timing sensitivity - valuation impact: a 6-12 month regulatory delay on a late-stage product can defer peak revenue by ~10-20% PV impact depending on discount rates and market size assumptions.
- Product concentration scenario: loss of a top product to generic/competitor entry could reduce revenue by an estimated 30-50% in 12-24 months absent offsetting launches.
- Supply shock scenario: a sustained 20% increase in key input prices could reduce gross margin by ~8-10 percentage points, turning modest net profits into losses on current cost structure.
- Reimbursement downside: a 10% cut in public reimbursement pricing for key products could reduce EBIT by ~15-25% depending on fixed-cost absorption.
- Talent risk: replacement of senior R&D leadership can extend development timelines by 6-9 months and increase R&D spend by ~5-10% due to ramp-up and consultancy needs.
- Progression of clinical milestones and regulatory filings (dates and outcomes).
- Revenue concentration metrics (top 3 products % of total sales).
- Gross margin trend and COGS per unit for flagship products.
- R&D spend as % of revenue and quarterly cash burn.
- Receivables aging and hospital procurement payment cycles (working-capital pressure).
- Changes to China national reimbursement lists or provincial procurement policies affecting pricing.
Anhui Anke Biotechnology Co., Ltd. (300009.SZ) - Growth Opportunities
The global macro tailwinds for biotechnology position Anhui Anke Biotechnology Co., Ltd. (300009.SZ) to scale, diversify, and capture share across high-growth therapeutic areas. Key opportunity vectors combine large addressable markets, strategic partnerships, R&D expansion, geographic diversification, digital health adoption, and manufacturing optimization.- Large and expanding end markets: global oncology therapeutics market ~USD 240-260 billion (2023) with a projected CAGR ~7-8% (2024-2030); global endocrinology (diabetes and hormonal disorders) drug market ~USD 90-110 billion (2023) with CAGR ~6-7%.
- China domestic biotech growth: China's biopharma market continues to grow faster than developed markets, with annual growth rates often reported in the mid-to-high single digits; specialty biologics and oncology agents are outpacing overall market growth.
- Addressable market opportunity for differentiated biologics and combination therapies: even single specialty indications can represent >USD 500M-1B lifetime sales for successful products.
| Opportunity Area | Estimated 2023 Size | Projected CAGR (2024-2030) | Implication for Anhui Anke |
|---|---|---|---|
| Oncology therapeutics | USD 240-260B | 7-8% | High revenue potential for targeted biologics; strategic licensing can accelerate entry. |
| Endocrinology (diabetes & hormonal) | USD 90-110B | 6-7% | Chronic disease pipelines offer recurring revenue and larger patient pools. |
| Emerging markets (ASEAN, Africa, LATAM) | Combined opportunity USD 30-70B | 8-12% | Lower-cost manufacturing + regulatory partnerships can unlock volume growth. |
| Digital health & telemedicine integration | Global digital health market ~USD 230B (2023) | 10-15% | Enhances patient access, adherence, and real-world data generation for products. |
- Strategic partnerships and collaborations: licensing, co-development, and distribution deals with international pharma can reduce time-to-market and share development risk. Target partners for late-stage assets can improve valuation multiples-industry M&A and licensing deals in oncology often exceed USD 100-500M upfront or milestone packages.
- R&D investment & pipeline diversification: moving beyond concentration in a few lead products to a portfolio that spans small molecules, biologics, and combination modalities reduces single-product risk. Benchmark R&D intensity in biotech peers typically ranges 15-30% of revenue during heavy development phases.
- Emerging market expansion: prioritizing regulatory alignment, local partnerships, and tiered-pricing models in markets with growing healthcare spend can add meaningful top-line growth without proportionate R&D spend.
- Digital capability buildout: integrating telemedicine, remote patient monitoring, and digital adherence tools can expand reach for endocrinology products and support chronic care models-digital strategies have been shown to increase adherence by 10-30% in pilot programs.
- Sustainable & cost-effective manufacturing: adopting single-use bioreactors, process intensification, and yield-improvement initiatives can lower COGS, improving gross margins potentially by several percentage points. Contract manufacturing partnerships can accelerate capacity scaling with lower capital expenditure.
- Value-capture levers and near-term KPIs to monitor:
- Number/value of licensing deals and upfront payments (target: ≥USD 10-50M per meaningful asset partnership).
- R&D spend as % of revenue and number of INDs/clinical trial starts per year (growth in INDs signals pipeline momentum).
- Geographic revenue diversification (% revenue outside China), and margins by geography.
- Manufacturing utilization rate and COGS per unit-improvements here drive operating leverage.
Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.